LianBio - ADR

NASDAQ:LIAN  
2.45
-0.04 (-1.61%)
Products, Regulatory

LianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data From Second Pivotal Trial Of TP-03 For The Treatment Of Demodex Blepharitis

Published: 05/03/2022 12:50 GMT
LianBio - ADR (LIAN) - Lianbio Partner Tarsus Pharmaceuticals Announces Positive Topline Data From Second Pivotal Trial of Tp-03 for the Treatment of Demodex Blepharitis.
Tarsus Pharmaceuticals - Tp-03 Met Primary Endpoint and All Secondary Endpoints in Saturn-2 Pivotal Phase 3 Trial With a Favorable Safety Profile.
Tarsus Pharmaceuticals - Plans to Submit a New Drug Application for Tp-03 to U.S. FDA in Second Half of 2022.